Quoin Pharmaceuticals, Ltd.
QNRX
$6.97
-$0.18-2.52%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 9.42% | 11.23% | 9.48% | 7.77% | 4.33% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 50.94% | 58.38% | 70.97% | 51.75% | 41.90% |
| Operating Income | -50.94% | -58.38% | -70.97% | -51.75% | -41.90% |
| Income Before Tax | -53.38% | -62.63% | -76.34% | -58.23% | -47.01% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -53.38% | -62.63% | -76.34% | -58.23% | -47.01% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -53.38% | -62.63% | -76.34% | -58.23% | -47.01% |
| EBIT | -50.94% | -58.38% | -70.97% | -51.75% | -41.90% |
| EBITDA | -51.35% | -58.91% | -71.72% | -52.32% | -42.40% |
| EPS Basic | 71.18% | 66.62% | 73.99% | 77.02% | 78.25% |
| Normalized Basic EPS | 71.18% | 66.62% | 73.99% | 77.02% | 78.25% |
| EPS Diluted | 71.39% | 66.78% | 73.83% | 76.93% | 78.09% |
| Normalized Diluted EPS | 71.18% | 66.62% | 73.99% | 77.02% | 78.25% |
| Average Basic Shares Outstanding | 484.30% | 517.45% | 708.09% | 414.94% | 473.96% |
| Average Diluted Shares Outstanding | 486.15% | 520.74% | 715.44% | 416.82% | 475.68% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |